Brief: Ryvu Therapeutics Extends Research Collaboration And Exclusive License Agreement With BioNTech Until Nov 29, 2028
March 16 (Reuters) - Ryvu Therapeutics SA RVU.WA: EXTENDS RESEARCH COLLABORATION AND EXCLUSIVE LICENSE AGREEMENT WITH BIONTECH SE AGREEMENT EXTENDED FOR AN ADDITIONAL YEAR, UNTIL NOVEMBER 29, 2028 Source text: ID:nEM2z8snsa Further company coverage: RVU.WA (Reporting by Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Ryvu Therapeutics SA
See all newsBrief: Ryvu Therapeutics Signs Grant Agreement For Panacea-Novo Project With The National Center For Research And Development
Brief: Ryvu Therapeutics Q2 Net Loss 13.1 Million Zlotys
Brief: Ryvu Therapeutics "Dualis" Project Recommended For 22.2 Mln Zloty Subsidy
Brief: Ryvu Therapeutics Launches Early Clinical Development Services Business For Biotech And Pharma In Europe
Brief: Ryvu Therapeutics Says Panacea-Novo Project Recommended For Funding Of 106.7 Mln Zlotys